# DEHYDROACETIC ACID (dehydroacetic-acid) — Global Cosmetic Regulatory & Formulation Monograph

- **Canonical URL**: https://www.inciname.com/en/ingredients/dehydroacetic-acid
- **Standard INCI**: `DEHYDROACETIC ACID`
- **KR MFDS Standard Name**: `데하이드로아세틱애씨드`
- **CAS No.**: `520-45-6`
- **EC / EINECS No.**: `208-293-9`
- **Origin**: `synthetic`
- **Functions**: 방부제
- **Molecular Formula / MW**: `—` (— g/mol)

## 1. 7-Track Official Regulatory Label Names
| Track | Official Label Nomenclature |
| :--- | :--- |
| KR (MFDS Standard) | 데하이드로아세틱애씨드 |
| KR (Former Names) | — |
| EU (CosIng 1223/2009) | DEHYDROACETIC ACID |
| US (PCPC / MoCRA INCI) | DEHYDROACETIC ACID |
| US (FDA OTC Monograph) | — |
| CN (NMPA IECIC) | 脱氢乙酸 |
| JP (JCIA / MHLW QD) | DEHYDROACETIC ACID  |

## 2. Layer 1 — Global 6-Region Statutory Summary
- **KR (MFDS)**: `restricted`
- **EU (1223/2009)**: `restricted`
- **US (FDA/MoCRA)**: `none`
- **CN (NMPA IECIC)**: `allowed` (Entry: `6747`)
- **JP (MHLW)**: `none`
- **ASEAN (ACD)**: `none`



## 3. Layer 2 — Toxicological & Historical Safe Use Concentrations
- Listed within general cosmetic GMP safety thresholds.

## 4. Layer 3 — Formulation Quartiles & Compatibility
- **Optimal pH Window**: 4 – 8
- **Max Process Temp**: ≤ 50°C
- **Synergy Pairings**: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL
- **Incompatibilities**: Verify phase compatibility under extreme pH or high electrolyte loads

## 5. Academic Monograph
■ [1. Chemical Identity & International Labeling Nomenclature]
  - INCI Name: DEHYDROACETIC ACID | CAS No.: 520-45-6 | EC No.: 208-293-9
  - Origin: SYNTHETIC | Functions: 
  - Physicochemical Profile: Formula      | MW /(Polymer/Complex) | /   | Ionic Nature: non-ionic | CosIng/MFDS 
  - Official Regional Label Names: US [DEHYDROACETIC ACID] · EU [DEHYDROACETIC ACID] · CN [脱氢乙酸] · JP [-] · JP Quasi-Drug [-]
■ [2. Dermatological Mechanism of Action & Functional Role]
  - Dehydroacetic Acid is the cyclic ketone that conforms to the formula: Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver  performance and structural formulation stability.
■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)]
  - Regional Summary: KR: RESTRICTED | EU: RESTRICTED | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 6747 (脱氢乙酸))
  - [KR / COMPOSITION / limited] (Max 0.6%): 
  - [EU / COMPOSITION / limited] (Max 0.6%): 
  - Official Safety & Historical Use Concentration (Layer 2): Quantum satis (QS) within standard cosmetic safety margins
■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)]
  - [emulsion_cream] Typical range: 0.2 ~ 0.8% (Median 0.8%, Ref: Global Starter Formulation Library Statistical Distribution (n=7, SEPPIC 7)) — Emulsion cream & lotion structural / conditioning agent
■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)]
  - Addition Phase: Water Phase or Cool-down Phase (< 45°C)
  - Optimal pH Range: pH 4.0 ~ 8.0 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM
  - Incompatibility / Caution: Verify phase compatibility under extreme pH or high electrolyte loads
  - Synergy Pairings: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL | Reference Trade Names: DEHYDROACETIC ACID
■ [6. Peer-Reviewed Literature & Official Compendia Evidence]
  - PMID 41666436 (2026, J Appl Toxicol): In Vitro Percutaneous Absorption of Dehydroacetic Acid and Benzoic Acid From Pig Skin Using the Franz Diffusion Cell Sys
  - PMID 38913451 (2024, Int J Toxicol): Sodium Dehydroacetate and Dehydroacetic Acid
  - PMID 38103582 (2024, Toxicol Lett): The mechanism of blood coagulation induced by sodium dehydroacetate via the regulation of the mTOR/ERK pathway in rats

## 6. Linked PubMed Literature
- [PMID: 41666436] In Vitro Percutaneous Absorption of Dehydroacetic Acid and Benzoic Acid From Pig Skin Using the Franz Diffusion Cell System — *J Appl Toxicol* (2026)
- [PMID: 38913451] Sodium Dehydroacetate and Dehydroacetic Acid — *Int J Toxicol* (2024)
- [PMID: 38103582] The mechanism of blood coagulation induced by sodium dehydroacetate via the regulation of the mTOR/ERK pathway in rats — *Toxicol Lett* (2024)
- [PMID: 37972261] Dehydroacetic acid a privileged medicinal scaffold: A concise review — *Arch Pharm (Weinheim)* (2024)
- [PMID: 36849039] Cosmeceutical formulations of pro-vitamin E phosphate: In-vitro release testing and dermal penetration into excised human skin — *Int J Pharm* (2023)
- [PMID: 36403723] Mechanism of VKORC1 and VKORC1L1 signaling in the effects of sodium dehydroacetate on coagulation factors in rat hepatocytes — *Toxicol In Vitro* (2023)
- [PMID: 33624850] Integrated approaches to testing and assessment as a tool for the hazard assessment and risk characterization of cosmetic preservatives — *J Appl Toxicol* (2021)
- [PMID: 33396133] Sodium dehydroacetate induces cardiovascular toxicity associated with Ca(2+) imbalance in zebrafish — *Ecotoxicol Environ Saf* (2021)
- [PMID: 33131684] Sodium dehydroacetate exposure decreases locomotor persistence and hypoxia tolerance in zebrafish — *Environ Res* (2021)
- [PMID: 31078787] Sodium dehydroacetate induces coagulation dysfunction by inhibiting liver vitamin K epoxide reductase complex subunit 1 in Wistar rats — *Res Vet Sci* (2019)
- [PMID: 30900864] Determination of 25 preservatives in cosmetics by gas chromatography-tandem mass spectrometry — *Se Pu* (2019)
- [PMID: 40885155] Nontarget screening and identification of emerging preservatives and their metabolites in human urine — *J Chromatogr A* (2025)